DRTS Alpha Tau Medical Ltd. Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1871321 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-34.3%
TTM EPS YoY-17.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-61.0%
ROA-44.4%
ROIC (approx.)-58.7%
Asset turnover—
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio7.45x
Interest coverage-121.87x
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $32.06M | $27.02M |
| SG&A expense | $8.36M | $6.67M |
| Operating income | -$42.29M | -$36.04M |
| Interest expense | $347,000 | $303,000 |
| Pretax income | -$42.51M | -$31.74M |
| Income tax | $121,000 | $6,000 |
| Net income | -$42.63M | -$31.75M |
| EBITDA | -$41.06M | -$34.94M |
| EPS (basic) | -0.53 | -0.45 |
| EPS (diluted) | -0.53 | -0.45 |
| Weighted avg. shares (diluted) | 80.58M | 69.93M |
| Balance sheet | ||
| Cash & equivalents | $12.20M | $13.72M |
| Short-term investments | $60.92M | $45.88M |
| Current assets | $78.30M | $64.23M |
| PP&E, net | $19.66M | $13.93M |
| Total assets | $105.65M | $86.20M |
| Current liabilities | $10.51M | $8.68M |
| Total liabilities | $28.55M | $23.54M |
| Shareholders' equity | $77.10M | $62.67M |
| Shares outstanding | 88.01M | 70.38M |
| Cash flow statement | ||
| Operating cash flow | -$26.68M | -$19.78M |
| Capital expenditure | $6.08M | $2.24M |
| Free cash flow | -$32.76M | -$22.02M |
| Investing cash flow | -$20.59M | $20.77M |
| Financing cash flow | $45.77M | $25,000 |
| Depreciation & amortization | $1.23M | $1.10M |
| Stock-based compensation | $10.62M | $9.92M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.